Micro Therapeutics' balloon catheter:
This article was originally published in Clinica
The US FDA has cleared Micro Therapeutics' balloon catheter system for selectively stopping or controlling blood flow in small peripheral blood vessels. The Equinox occlusion balloon system can access tortuous anatomy and can stop blood flow to distal sites allowing vascular abnormalities to be embolised. The device, which will be used with the company's SilverSpeed hydrophilic guidewire, was released in Europe earlier this year where it will be distributed by Guidant. Irvine, California-based Micro Therapeutics will distribute the product in the US.
You may also be interested in...
COVID-19 Vaccines: ACIP’s Allocation Proposal Prioritizes Long-Term Care Residents, Essential Workers
First group to receive vaccine would comprise health care personnel and residents of long-term care facilities; next in line are non-health care essential workers, who would take priority over adults with high-risk medical conditions and those ages 65 years and older, according to the CDC advisory committee’s proposed allocation framework.
Azar says ACIP’s prioritization recommendations should carry weight, but states will be final arbiter of who is vaccinated.
Sanofi R&D head John Reed says the company has kept 95% of patients on its nearly 400 clinical trials, started 59 studies, and benefited from its in-house drug supply management.